MedPath

An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon

Phase 1
Terminated
Conditions
Colon Cancer
Interventions
Registration Number
NCT01344902
Lead Sponsor
Photocure
Brief Summary

The purpose of the study is to determine if it is possible to detect more pre-cancerous lesions in colon when using fluorescence technology.

Detailed Description

Carcinoma of the lower GI-tract is among the leading malignancies in the western world causing a substantial morbidity, mortality and consequently a large burden to the health care system in the diagnosis, treatment and follow-up of these patients.

The primary objectives of this study is to determine carcinoma- and adenoma lesion true detection rate of HAL fluorescence colonoscopy in patients with known or strong suspicion of neoplasia in the colon. The secondary objective and endpoints are to determine carcinoma- and adenoma lesion false detection rate of HAL fluorescence colonoscopy, to compare carcinoma- and adenoma lesion true detection rates and the false detection rates of fluorescence with standard colonoscopy and to characterize the safety profile of HAL fluorescence colonoscopy.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • Female and Male subjects with known or strong suspicion iof adenoma or carcinoma of the colon after screening of follow-up colonoscopy
  • Female and male patients with verified neoplastic lesions
Exclusion Criteria
  • Known or strong suspected porphyria
  • Contraindications to colonoscopy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Hexaminolevulinatehexaminolevulinate HCl-
Primary Outcome Measures
NameTimeMethod
Determine the carcinoma- and adenoma lesion true detection rateBaseline
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Klinikum München Pasing

🇩🇪

Munich, Germany

© Copyright 2025. All Rights Reserved by MedPath